Close Menu
NEW YORK (GenomeWeb News) — Emiliem and Invitrogen will screen Emiliem’s multi-kinase inhibitors under a partnership agreement, the companies said today.
 
The companies said they will use Invitrogen’s SelectScreen for kinase and P450 screening and cellular pathway profiling to study Emiliem’s cancer compounds.  
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.